Antimetastatic role of Smad4 signaling in colorectal cancer.

BACKGROUND & AIMS Transforming growth factor (TGF)-beta signaling occurs through Smads 2/3/4, which translocate to the nucleus to regulate transcription; TGF-beta has tumor-suppressive effects in some tumor models and pro-metastatic effects in others. In patients with colorectal cancer (CRC), mutations or reduced levels of Smad4 have been correlated with reduced survival. However, the function of Smad signaling and the effects of TGF-beta-receptor kinase inhibitors have not been analyzed during CRC metastasis. We investigated the role of TGF-beta/Smad signaling in CRC progression. METHODS We evaluated the role of TGF-beta/Smad signaling on cell proliferation, migration, invasion, tumorigenicity, and metastasis in Smad4-null colon carcinoma cell lines (MC38 and SW620) and in those that transgenically express Smad4. We also determined the effects of a TGF-beta-receptor kinase inhibitor (LY2109761) in CRC tumor progression and metastasis in mice. RESULTS TGF-beta induced migration/invasion, tumorigenicity, and metastasis of Smad4-null MC38 and SW620 cells; incubation with LY2109761 reversed these effects. In mice, LY2109761 blocked metastasis of CRC cells to liver, inducing cancer cell expression of E-cadherin and reducing the expression of the tumorigenic proteins matrix metalloproteinase-9, nm23, urokinase plasminogen activator, and cyclooxygenase-2. Transgenic expression of Smad4 significantly reduced the oncogenic potential of MC38 and SW620 cells; in these transgenic cells, TGF-beta had tumor suppressor, rather than tumorigenic, effects. CONCLUSIONS TGF-beta/Smad signaling suppresses progression and metastasis of CRC cells and tumors in mice. Loss of Smad4 might underlie the functional shift of TGF-beta from a tumor suppressor to a tumor promoter; inhibitors of TGF-beta signaling might be developed as CRC therapeutics.

[1]  N. Deane,et al.  Smad7 induces hepatic metastasis in colorectal cancer , 2008, British Journal of Cancer.

[2]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[3]  G. Giannelli,et al.  Blocking transforming growth factor–beta up‐regulates E‐cadherin and reduces migration and invasion of hepatocellular carcinoma cells , 2008, Hepatology.

[4]  G. Tortora,et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.

[5]  J. Benhattar,et al.  Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. , 2007, Oncology reports.

[6]  K. Mohammad,et al.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. , 2007, Cancer research.

[7]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.

[8]  Xiu-fen Lei,et al.  Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.

[9]  K. Miyazono,et al.  Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. , 2005, Journal of the National Cancer Institute.

[10]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  V. Robinson,et al.  Metastasis suppressor genes: From gene identification to protein function and regulation , 2005, Cancer biology & therapy.

[12]  R. Beauchamp,et al.  A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. , 2005, Neoplasia.

[13]  Jukka-Pekka Mecklin,et al.  SMAD4 as a Prognostic Marker in Colorectal Cancer , 2005, Clinical Cancer Research.

[14]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[15]  M. Sarris,et al.  nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  J. Massagué,et al.  Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-β Antiproliferative Responses in Colon Cancer Cells* , 1999, The Journal of Biological Chemistry.

[17]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[18]  S. Al-Sedairy,et al.  High levels of Nm23 gene expression in advanced stage of thyroid carcinomas. , 1993, British Journal of Cancer.

[19]  G. Kaur,et al.  Nuclear localization and intensity of staining of nm23 protein is useful marker for breast cancer progression , 2008, Cancer Cell International.

[20]  J. Mann,et al.  Transforming Growth Factor-β (TGF-β) Signaling Inhibitors in Cancer Therapy , 2008 .

[21]  M. Laiho,et al.  Transforming Growth Factor-β in Cancer Therapy , 2008 .

[22]  J. Behrens,et al.  Cadherins and Catenins: Role in Signal Transduction and Tumor Progression , 2004, Cancer and Metastasis Reviews.

[23]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[24]  J. Benhattar,et al.  Loss of Smad 4 expression predicts liver metastasis in human colorectal cancer , 2022 .